Detection and quantification of soluble intercellular adhesion molecule-1 (sICAM-1) in the serum and urine of patients with bladder cancer.
A possible role for intercellular adhesion molecules in tumor progression and metastasis has been strongly suggested. To investigate the effect of soluble intercellular adhesion molecule-1 (sICAM-1) on bladder cancer, sICAM-1 serum and urinary concentrations were measured in patients with superficial or invasive bladder cancer and in patients with prostatic hypertrophy. Serum and urine samples were obtained from 26 patients with transitional cell carcinoma of the bladder (mean age, 66.8 years) and 14 patients with benign prostatic hypertrophy (BPH; mean age, 70.5 years). Fifteen healthy volunteers served as control patients. Samples were collected before surgery and 5 days after surgery. The serum and urinary slCAM-1 levels were measured by an ELISA. The preoperative serum concentration of sICAM-1 was significantly higher in patients with invasive bladder cancer (351.8+/-158.0 ng/mL) than in the healthy controls (233.1+/-96.1 ng/mL; P< 0.05) or BPH patients (224.7+/-80.5 ng/mL; P< 0.05). In addition, serum sICAM-1 levels were significantly higher in patients with tumors greater than 3 cm in size (412.7+/-147.6 ng/mL) than in patients with smaller tumors (246.6+/-101.2 ng/mL; P<0.05). Urinary sICAM-1 levels in patients with invasive bladder cancer were also significantly higher than in the patients with superficial cancer prior to surgery. Our results suggested that sICAM-1 may play an important role in the progression of bladder cancer, and that elevated serum sICAM-1 levels may be related to tumor size.